These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19480962)

  • 21. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing human papillomavirus vaccine efficacy and safety.
    Hendrix SL
    J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats.
    Wise LD; Wolf JJ; Kaplanski CV; Pauley CJ; Ledwith BJ
    Birth Defects Res B Dev Reprod Toxicol; 2008 Dec; 83(6):561-72. PubMed ID: 19025783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
    Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
    Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chapter 13: Current findings from prophylactic HPV vaccine trials.
    Koutsky LA; Harper DM
    Vaccine; 2006 Aug; 24 Suppl 3():S3/114-21. PubMed ID: 16949998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia.
    Pathirana D; Hillemanns P; Petry KU; Becker N; Brockmeyer NH; Erdmann R; Gissmann L; Grundhewer H; Ikenberg H; Kaufmann AM; Klusmann J; Kopp I; Pfister H; Rzany B; Schneede P; Schneider A; Smola S; Winter-Koch N; Wutzler P; Gross G
    Vaccine; 2009 Jul; 27(34):4551-9. PubMed ID: 19524337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.
    Brown DR; Fife KH; Wheeler CM; Koutsky LA; Lupinacci LM; Railkar R; Suhr G; Barr E; Dicello A; Li W; Smith JF; Tadesse A; Jansen KU
    Vaccine; 2004 Jul; 22(21-22):2936-42. PubMed ID: 15246630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
    Harper DM
    Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
    J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model.
    Choi YH; Chapman R; Gay N; Jit M
    Vaccine; 2012 May; 30(23):3383-8. PubMed ID: 22480925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic HPV vaccination for women over 18 years of age.
    Adams M; Jasani B; Fiander A
    Vaccine; 2009 May; 27(25-26):3391-4. PubMed ID: 19200838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global stability of equilibria in a two-sex HPV vaccination model.
    Elbasha EH
    Bull Math Biol; 2008 Apr; 70(3):894-909. PubMed ID: 17999117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
    Guevara A; Cabello R; Woelber L; Moreira ED; Joura E; Reich O; Shields C; Ellison MC; Joshi A; Luxembourg A
    Vaccine; 2017 Sep; 35(37):5050-5057. PubMed ID: 28789851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of antibody response to HPV vaccination in HIV infected girls].
    Ołdakowska A; Marczyńska M; Dobosz S; Stańska-Perka A; Popielska J; Szczepańska-Putz M
    Przegl Epidemiol; 2012; 66(4):651-5. PubMed ID: 23484395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human papillomavirus vaccines and anal carcinoma.
    Franceschi S; De Vuyst H
    Curr Opin HIV AIDS; 2009 Jan; 4(1):57-63. PubMed ID: 19339940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
    Barthell E; Woelber L; Hellner K; Camerer B; Gieseking F; Hauschild M; Mylonas I; Friese K; Sings HL; Railkar R; Gause C; Barr E
    Arch Gynecol Obstet; 2009 Jun; 279(6):803-7. PubMed ID: 18936950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural differences among cost-effectiveness models of human papillomavirus vaccines.
    Insinga RP; Dasbach EJ; Elbasha EH
    Expert Rev Vaccines; 2008 Sep; 7(7):895-913. PubMed ID: 18767941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
    Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.
    Herrero R
    J Infect Dis; 2009 Apr; 199(7):919-22. PubMed ID: 19236278
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluating the impact of human papillomavirus vaccines.
    Chang Y; Brewer NT; Rinas AC; Schmitt K; Smith JS
    Vaccine; 2009 Jul; 27(32):4355-62. PubMed ID: 19515467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.